Drugs for Gastrointestinal Diseases Practice Questions

Q: A patient on cisplatin therapy develops intractable vomiting on the third day of treatment. What is the agent of choice for controlling this vomiting?

Aprepitant. ### Explanation **Correct Answer: A. Aprepitant** The key to this question lies in the timing of the vomiting. Cisplatin is a highly emetogenic chemotherapy agent that causes two distinct phases of nausea and vomiting: 1. **Acute Phase (within 24 hours):** Primarily mediated by **Serotonin (5-HT3)** release from enterochromaffin cells. 2. **Delayed Phase (24 hours to 5 days):** Primarily mediated by **Substance P** acting on **Neurokinin-1 (NK1) receptors** in the area postrema. Since the patient is on the **third day** of treatment, they are experiencing **delayed emesis**. **Aprepitant** is a selective NK1 receptor antagonist specifically indicated for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV). **Why other options are incorrect:** * **B. Ondansetron:** This is a 5-HT3 antagonist. While it is the drug of choice for *acute* emesis (first 24 hours), it has limited efficacy in the *delayed* phase. * **C. Metoclopramide:** A D2 receptor antagonist. It is less effective than NK1 antagonists for cisplatin-induced emesis and carries a risk of extrapyramidal side effects. * **D. Prochlorperazine:** A phenothiazine (D2 antagonist) used for mild-to-moderate emesis; it is insufficient for the highly emetogenic profile of cisplatin. --- ### High-Yield Clinical Pearls for NEET-PG: * **Triple Therapy for Cisplatin:** The standard regimen for highly emetogenic chemotherapy is a combination of an **NK1 antagonist** (Aprepitant), a **5-HT3 antagonist** (Ondansetron), and a **Corticosteroid** (Dexamethasone). * **Aprepitant Metabolism:** It is an inhibitor and inducer of **CYP3A4**; it can increase plasma levels of dexamethasone (requiring dose reduction of the steroid). * **Netupitant/Rolapitant:** Newer NK1 antagonists with longer half-lives than Aprepitant. * **Palonosetron:** A second-generation 5-HT3 antagonist with a longer half-life that has some efficacy in delayed emesis, unlike Ondansetron.

Q: Which of the following drugs causes the observed effect on colonoscopic view?

Senna. ***Senna*** - Senna is an **anthraquinone laxative** that causes **melanosis coli**, a characteristic brown/black discoloration of the colonic mucosa visible on colonoscopy. - This pigmentation occurs due to **lipofuscin deposits** in macrophages within the colonic wall after chronic use of anthraquinone-containing laxatives. *Bisacodyl* - Bisacodyl is a **stimulant laxative** that works by increasing colonic motility and electrolyte secretion but does not cause pigmentation changes. - It acts on the **enteric nervous system** and does not deposit pigments in the colonic mucosa like anthraquinones do. *Bismuth* - Bismuth compounds can cause **black discoloration of the tongue and stool** but do not cause the characteristic mucosal pigmentation seen in melanosis coli. - The black stool from bismuth is due to **bismuth sulfide formation** in the gut, not mucosal pigment deposition. *Aluminium Hydroxide* - Aluminium hydroxide is an **antacid and phosphate binder** that can cause constipation but does not cause any characteristic colonoscopic findings. - It works by **neutralizing gastric acid** and binding phosphates, without affecting colonic mucosal appearance.

Q: Why is atropine added to commercial preparations containing diphenoxylate?

To prevent overdosage and discourage opioid dependence.. **Explanation:** **Diphenoxylate** is a synthetic opioid derivative chemically related to pethidine. It acts on the $\mu$-opioid receptors in the GI tract to decrease intestinal motility, making it an effective anti-diarrheal agent. However, at high doses, it can cross the blood-brain barrier and produce typical opioid effects (euphoria and sedation), leading to potential abuse. **1. Why Option C is Correct:** To discourage drug abuse and prevent overdosage, a sub-therapeutic dose of **Atropine** (an anticholinergic) is added to diphenoxylate (e.g., in the combination drug **Lomotil**). If a person attempts to take a large dose of the preparation to achieve a "high," they will experience the unpleasant side effects of atropine overdose, such as dry mouth, blurred vision, tachycardia, and urinary retention. This serves as a **chemical deterrent** against opioid dependence. **2. Why Other Options are Incorrect:** * **Option A:** While atropine has antispasmodic properties, this is not the primary pharmacological reason for its inclusion in this specific combination. * **Option B:** Diphenoxylate itself reduces the propulsion of intestinal contents; atropine does not significantly alter salt and water excretion in this context. * **Option D:** Atropine does not alter the metabolism or pharmacokinetics of diphenoxylate to prolong its duration. **High-Yield Clinical Pearls for NEET-PG:** * **Loperamide** is preferred over diphenoxylate because it is more selective for the GI tract, lacks central effects (due to P-glycoprotein efflux), and has **no abuse potential**; hence, it does not require atropine. * **Contraindication:** Both drugs are contraindicated in infectious diarrhea (e.g., *Salmonella*, *Shigella*) as they may delay the clearance of toxins, leading to toxic megacolon. * **Treatment of Overdose:** Naloxone is the antidote for diphenoxylate toxicity.

Q: Which of the following is NOT a gastrointestinal effect of metoclopramide?

Alters colonic motility. ### Explanation Metoclopramide is a **prokinetic agent** that acts as a **D2-receptor antagonist** and a **5-HT4 receptor agonist**. Its primary clinical utility lies in its ability to coordinate and enhance motility in the upper gastrointestinal tract. **1. Why "Alters colonic motility" is correct:** Metoclopramide’s prokinetic effects are restricted to the **upper GI tract** (esophagus, stomach, and small intestine). It has **no significant effect on lower GI motility or colonic transit time**. Therefore, it is ineffective for conditions like constipation or colonic pseudo-obstruction. **2. Analysis of Incorrect Options:** * **Accelerates gastric emptying:** By antagonizing D2 receptors (which normally inhibit ACh release) and stimulating 5-HT4 receptors, metoclopramide increases the release of Acetylcholine. This enhances gastric antral contractions and relaxes the pyloric sphincter, speeding up emptying. * **Reduces reflux from the stomach into the esophagus:** It increases the **Lower Esophageal Sphincter (LES) tone**, which prevents the retrograde flow of gastric acid, making it useful in GERD. * **Decreases the bioavailability of digoxin:** Because it speeds up gastric emptying and intestinal transit, drugs that require slow dissolution or have limited absorption sites (like digoxin or levodopa) may have decreased bioavailability. Conversely, it can accelerate the absorption of drugs like paracetamol or aspirin. ### High-Yield NEET-PG Pearls * **Mechanism:** D2 Antagonist (central & peripheral) + 5-HT4 Agonist + 5-HT3 Antagonist (at high doses). * **Anti-emetic Action:** Occurs via the **Chemoreceptor Trigger Zone (CTZ)**. * **Side Effects:** Extrapyramidal symptoms (dystonia, parkinsonism) due to central D2 blockade; **Hyperprolactinemia** (causing galactorrhea/amenorrhea). * **Drug of Choice:** Often used for Diabetic Gastroparesis and as an anti-emetic in postoperative states.

Q: What is the most common side effect of the 5-HT3 antagonist drug alosetron?

Constipation. **Explanation:** **Alosetron** is a potent and selective **5-HT3 receptor antagonist** specifically used for the treatment of severe, diarrhea-predominant Irritable Bowel Syndrome (IBS-D) in women. **1. Why Constipation is the correct answer:** 5-HT3 receptors in the gastrointestinal tract play a crucial role in regulating visceral sensation and intestinal motility. By blocking these receptors, alosetron slows colonic transit time and increases water absorption. Consequently, **constipation** is the most frequent side effect, occurring in approximately 25-30% of patients. A more severe and life-threatening complication associated with alosetron is **ischemic colitis**, which led to its temporary withdrawal from the market (it is now available under a restricted prescribing program). **2. Why the other options are incorrect:** * **Pulmonary fibrosis:** This is a classic side effect of drugs like busulfan, bleomycin, and amiodarone, but it is not associated with 5-HT3 antagonists. * **Cardiac arrhythmias:** While other 5-HT3 antagonists used for emesis (like **Ondansetron**) are known to cause **QT interval prolongation**, this is not the primary or most common concern for alosetron. * **Headache:** Although headache is the most common side effect of *anti-emetic* 5-HT3 antagonists (e.g., Ondansetron), in the specific context of alosetron and IBS-D, constipation is significantly more prevalent and clinically relevant. **NEET-PG High-Yield Pearls:** * **Indication:** Only for **women** with severe **IBS-D** who haven't responded to conventional therapy. * **Black Box Warning:** Risk of severe constipation and **ischemic colitis**. * **Mechanism:** Reduces GI motility and decreases "visceral hypersensitivity" (pain). * **Comparison:** For IBS-Constipation (IBS-C), the 5-HT4 agonist **Tegaserod** or the chloride channel activator **Lubiprostone** are used.

Q: The inhibition of hydrochloric acid (HCl) secretion by omeprazole occurs within an hour, reaches a peak at 2 hours, and plateaus by the 4th day. After how many days will the secretion gradually normalize?

3-5 days. ### Explanation **Correct Answer: C. 3-5 days** **Mechanism of Action:** Omeprazole is a **Proton Pump Inhibitor (PPI)** that acts by irreversibly binding to the $H^+/K^+$-ATPase enzyme (the "proton pump") in the gastric parietal cells via covalent disulfide bonds. Because the inhibition is **irreversible**, the recovery of acid secretion does not depend on the drug's plasma half-life (which is short, ~1 hour), but rather on the **synthesis of new proton pumps**. It takes approximately **3 to 5 days** for the body to regenerate enough new $H^+/K^+$-ATPase molecules to restore gastric acid secretion to its baseline level. **Analysis of Incorrect Options:** * **Option A ( 5 days):** While some residual effect may linger, the clinically significant normalization of acid secretion typically occurs within the 3-5 day window as the turnover of parietal cell proteins is relatively rapid. **NEET-PG High-Yield Pearls:** * **Prodrug Status:** PPIs are inactive at neutral pH; they are basic compounds that require an **acidic environment** (within the canaliculi of parietal cells) to be converted into the active **sulfenamide** form. * **Administration Timing:** PPIs should be taken **30–60 minutes before a meal** (usually breakfast) because the number of $H^+/K^+$-ATPase pumps at the canalicular surface is maximal after a period of fasting. * **Steady State:** It takes 3-4 days of continuous dosing to reach a "plateau" or steady-state inhibition (approx. 70% of pumps), which correlates with the time it takes for the recovery of secretion.

Q: Certolizumab is used in the treatment of:

Crohn's disease. **Explanation:** **Certolizumab pegol** is a recombinant, humanized antibody fragment (Fab') conjugated to polyethylene glycol (PEG). It acts as a potent **TNF-α (Tumor Necrosis Factor-alpha) inhibitor**. 1. **Why Crohn’s Disease is Correct:** TNF-α is a key pro-inflammatory cytokine involved in the pathogenesis of Inflammatory Bowel Disease (IBD). Certolizumab neutralizes both membrane-bound and soluble TNF-α, reducing intestinal inflammation. It is specifically FDA-approved for reducing signs and symptoms and maintaining clinical response in adult patients with moderately to severely active **Crohn's disease** who have had an inadequate response to conventional therapy. 2. **Why Other Options are Incorrect:** * **Multiple Sclerosis (MS):** TNF-α inhibitors are generally **contraindicated** in MS as they can exacerbate demyelinating diseases. MS is typically treated with Interferon-beta, Glatiramer acetate, or Natalizumab. * **Colorectal Carcinoma:** This is treated with chemotherapy and targeted therapies like Bevacizumab (anti-VEGF) or Cetuximab (anti-EGFR), not TNF inhibitors. * **SLF2:** This is not a recognized clinical entity relevant to TNF-inhibitor therapy (likely a distractor). **NEET-PG High-Yield Pearls:** * **Unique Structure:** Unlike Infliximab or Adalimumab, Certolizumab **lacks an Fc portion**. This prevents complement activation or antibody-dependent cellular cytotoxicity (ADCC). * **Pregnancy:** Because it lacks the Fc region, it does not undergo active placental transfer, making it a preferred TNF inhibitor during **pregnancy**. * **Pegylation:** The addition of PEG increases the half-life, allowing for subcutaneous dosing every 2–4 weeks. * **Other Indications:** Rheumatoid arthritis, Psoriatic arthritis, and Ankylosing spondylitis.

Q: Which of the following drugs is used in the management of drug-induced ulcers?

Omeprazole. **Explanation:** The management of drug-induced ulcers, particularly those caused by Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), focuses on potent acid suppression to allow the gastric mucosa to heal. **Why Omeprazole is the Correct Answer:** Proton Pump Inhibitors (PPIs) like **Omeprazole** are considered the **drugs of choice** for both the treatment and prevention of NSAID-induced gastric and duodenal ulcers. They work by irreversibly inhibiting the $H^+/K^+$-ATPase pump in gastric parietal cells. Clinical trials have consistently shown that PPIs are superior to $H_2$ blockers and Misoprostol in terms of healing rates and patient tolerance. **Analysis of Incorrect Options:** * **Antacids (A):** These provide symptomatic relief by neutralizing existing gastric acid but do not promote significant ulcer healing or provide long-term protection. * **Ranitidine (B):** While $H_2$ receptor antagonists can heal NSAID-induced duodenal ulcers, they are significantly **less effective** than PPIs for healing gastric ulcers (the more common site for NSAID injury). * **Misoprostol (D):** This is a $PGE_1$ analogue that replaces the prostaglandins depleted by NSAIDs. While it is highly effective for **prevention**, it is less effective than PPIs for **healing** active ulcers and is poorly tolerated due to side effects like abdominal cramps and diarrhea. **NEET-PG High-Yield Pearls:** * **Drug of Choice for NSAID-induced ulcers:** PPIs (e.g., Omeprazole). * **Specific Prostaglandin Analogue for Prevention:** Misoprostol (specifically indicated for preventing NSAID-induced ulcers in high-risk patients). * **Most common site for NSAID ulcers:** Stomach (Gastric ulcer). * **Most common site for H. pylori ulcers:** Duodenum.

Q: Which of the following is the drug of choice for the treatment of peptic ulcer disease?

Omeprazole. **Explanation:** **Correct Option: A. Omeprazole** Proton Pump Inhibitors (PPIs) like Omeprazole are the **drug of choice (DOC)** for Peptic Ulcer Disease (PUD), including gastric and duodenal ulcers [1], [2]. They act by irreversibly inhibiting the **H+/K+ ATPase pump** (the final common pathway of acid secretion) in the gastric parietal cells [1]. PPIs are superior to other agents because they provide the most potent and prolonged inhibition of both basal and stimulated gastric acid secretion [2], achieving healing rates of >90% within 4–8 weeks. **Incorrect Options:** * **B. Pirenzepine:** This is a selective M1 muscarinic antagonist. While it reduces acid secretion, it is significantly less effective than PPIs and H2 blockers and is rarely used clinically due to anticholinergic side effects. * **C. Ranitidine:** An H2 receptor antagonist [1]. While previously a mainstay for PUD, it is less potent than PPIs because it only blocks the histamine pathway, leaving the gastrin and acetylcholine pathways active [2]. It also carries a risk of tachyphylaxis (tolerance). * **D. Sucralfate:** A cytoprotective agent that forms a physical barrier over the ulcer base. It is used as an adjuvant therapy but is not the primary drug of choice as it does not affect the underlying acid secretion. **High-Yield Clinical Pearls for NEET-PG:** * **Administration:** PPIs are prodrugs and should be taken **30–60 minutes before breakfast** for maximal efficacy (when the number of H+/K+ ATPase pumps is highest). * **H. pylori Eradication:** PPIs are a mandatory component of the "Triple Therapy" (PPI + Clarithromycin + Amoxicillin/Metronidazole) [1], [2]. * **Zollinger-Ellison Syndrome:** PPIs are also the drug of choice for this hypersecretory condition [1], [2]. * **Side Effects:** Long-term PPI use is associated with Vitamin B12 deficiency, hypomagnesemia, and an increased risk of *C. difficile* infections and osteoporotic fractures [2].

Q: Which laxative is used in the management of hepatic encephalopathy?

Lactulose. ### Explanation **Correct Option: A (Lactulose)** Lactulose is a non-absorbable disaccharide that serves as the mainstay of treatment for hepatic encephalopathy (HE) due to its unique dual mechanism: 1. **Ammonia Trapping:** Colonic bacteria ferment lactulose into lactic and acetic acids. This acidifies the gut lumen (lowers pH), converting diffusible ammonia ($NH_3$) into non-diffusible ammonium ions ($NH_4^+$), which are then excreted in the stool. 2. **Osmotic Laxation:** As an osmotic laxative, it increases fecal bulk and speeds up transit time, reducing the duration available for ammonia production and absorption by gut flora. **Incorrect Options:** * **B (Sodium picosulfate):** A stimulant laxative often used for bowel preparation before colonoscopy. It has no effect on ammonia metabolism. * **C (Lubiprostone):** A chloride channel activator (ClC-2) used for chronic idiopathic constipation and IBS-C. It does not lower systemic ammonia levels. * **D (Bisacodyl):** A diphenylmethane derivative stimulant laxative. While effective for acute constipation, it lacks the acidifying properties required to treat HE. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Goal:** In HE, lactulose dosage is titrated to achieve **2–3 soft stools per day**. * **Rifaximin:** Often added to lactulose for secondary prevention of HE; it is a non-absorbable antibiotic that kills ammonia-producing bacteria. * **Other uses of Lactulose:** It is also used to treat chronic constipation and can help prevent portal-systemic encephalopathy. * **Side Effects:** Flatulence, abdominal cramps, and electrolyte imbalance (due to diarrhea).

Question 1

A patient on cisplatin therapy develops intractable vomiting on the third day of treatment. What is the agent of choice for controlling this vomiting?

Accepted Answer

Aprepitant

Answer

Ondansetron

Answer

Metoclopramide

Answer

Prochlorperazine

Question 2

Which of the following drugs causes the observed effect on colonoscopic view?

Accepted Answer

Senna

Answer

Bisacodyl

Answer

Bismuth

Answer

Aluminium Hydroxide

Question 3

Why is atropine added to commercial preparations containing diphenoxylate?

Accepted Answer

To prevent overdosage and discourage opioid dependence.

Answer

To potentiate its anti-spasmodic effect.

Answer

To reduce the excretion of salt and water.

Answer

To prolong its duration of action.

Question 4

Which of the following is NOT a gastrointestinal effect of metoclopramide?

Accepted Answer

Alters colonic motility

Answer

Accelerates gastric emptying

Answer

Reduces reflex from the stomach into the esophagus

Answer

Decreases the bioavailability of digoxin

Question 5

What is the most common side effect of the 5-HT3 antagonist drug alosetron?

Accepted Answer

Constipation

Answer

Pulmonary fibrosis

Answer

Cardiac arrhythmias

Answer

Headache

Question 6

The inhibition of hydrochloric acid (HCl) secretion by omeprazole occurs within an hour, reaches a peak at 2 hours, and plateaus by the 4th day. After how many days will the secretion gradually normalize?

Accepted Answer

3-5 days

Answer

Less than 24 hours

Answer

1-2 days

Answer

More than 5 days

Question 7

Certolizumab is used in the treatment of:

Accepted Answer

Crohn's disease

Answer

Multiple Sclerosis

Answer

Colorectal Carcinoma

Answer

SLF2

Question 8

Which of the following drugs is used in the management of drug-induced ulcers?

Accepted Answer

Omeprazole

Answer

Antacids

Answer

Ranitidine

Answer

Misoprostol

Question 9

Which of the following is the drug of choice for the treatment of peptic ulcer disease?

Accepted Answer

Omeprazole

Answer

Pirenzepine

Answer

Ranitidine

Answer

Sucralfate

Question 10

Which laxative is used in the management of hepatic encephalopathy?

Accepted Answer

Lactulose

Answer

Sodium picosulfate

Answer

Lubiprostone

Answer

Bisacodyl

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?